Navigation Links
Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
Date:11/11/2011

SEATTLE, Nov. 11, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (the "Company") (NASDAQ and MTA: CTIC) announced today the results from its Annual Meeting of Shareholders (the "Annual Meeting") held on Friday, November 11, 2011.

At the Annual Meeting, shareholders elected James A. Bianco, M.D., Vartan Gregorian, Ph.D., and Frederick W. Telling, Ph.D. to serve on the Company' s Board of Directors until the Company' s 2014 Annual Meeting. Shareholders also elected Reed V. Tuckson, M.D. to serve on the Company's Board of Directors until the Company's 2013 Annual Meeting. Shareholders approved the proposals to amend the Company's amended and restated articles of incorporation to increase the total number of authorized shares and authorized shares of common stock and to make certain amendments to the Company' s 2007 Equity Incentive Plan, as amended and restated (the "Plan"), including an increase the number of shares available for issuance under the Plan. Shareholders also approved an advisory proposal on executive compensation and voted to hold an advisory vote on executive compensation every three years. Shareholders ratified the selection of Marcum LLP as the Company's independent auditors for the year ending December 31, 2011.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include the risk factors listed or described from time to time in CTI's filings with the U.S. Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
3. Cell Therapeutics, Inc. Announces Reverse Stock Split
4. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
6. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
10. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 2017 , ... NetDimensions has been ranked as a Leader ... Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who possess comprehensive ... those strategies. NetDimensionsā€™ ranking as a Leader due to its strengths in: , ...
(Date:5/23/2017)... Diego, CA (PRWEB) , ... May 23, 2017 , ... ... matrix of polymeric molecules, can cause diverse pathologies ranging from food poisoning and catheter ... impact of biofilms is in the tens of billions of dollars per year, there ...
(Date:5/22/2017)... ... 22, 2017 , ... Cancer diagnostics and pathology workflow solution ... the Association for Pathology Informatics Annual Summit at the Wyndham Grand ... Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research it led to ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs ... the Prince Of Wales Private Hospital. The procedure was performed on a 46-year-old ... failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is ...
Breaking Biology Technology:
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):